Sumitomo, Otsuka Both Stand To Gain From CNS Partnership

 
• By Alaric DeArment
  
Schizophrenia
Sumitomo and Otsuka have entered a deal of up to $890m centered on psychiatric drugs • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business